Lifetime risk of ESRD - PubMed (original) (raw)
Comparative Study
. 2012 Sep;23(9):1569-78.
doi: 10.1681/ASN.2012020164. Epub 2012 Aug 16.
Affiliations
- PMID: 22904351
- PMCID: PMC3431421
- DOI: 10.1681/ASN.2012020164
Comparative Study
Lifetime risk of ESRD
Tanvir Chowdhury Turin et al. J Am Soc Nephrol. 2012 Sep.
Abstract
Lifetime risk is the cumulative risk of experiencing an outcome between a disease-free index age and death. The lifetime risk of ESRD for a middle-aged individual is a relevant and easy to communicate measure of disease burden. We estimated lifetime risk of ESRD in a cohort of 2,895,521 adults without ESRD from 1997 to 2008. To estimate lifetime risk of ESRD by level of baseline kidney function, we analyzed a cohort of participants who had a serum creatinine measurement. We also estimated the sex- and index age-specific lifetime risk of incident ESRD and accounted for the competing risk of death. Among those individuals without ESRD at age 40 years, the lifetime risk of ESRD was 2.66% for men and 1.76% for women. The risk was higher in persons with reduced kidney function: for eGFR=44-59 ml/min per 1.73 m(2), the lifetime risk of ESRD was 7.51% for men and 3.21% for women, whereas men and women with relatively preserved kidney function (eGFR=60-89 ml/min per 1.73 m(2)) had lifetime risks of ESRD of 1.01% and 0.63%, respectively. The lifetime risk of ESRD was consistently higher for men at all ages and eGFR strata compared with women. In conclusion, approximately 1 in 40 men and 1 in 60 women of middle age will develop ESRD during their lifetimes (living into their 90s). These population-based estimates may assist individuals who make decisions regarding public health policy.
Figures
Figure 1.
Overview of cohort creation. (A) The primary study cohort consisted of Alberta residents aged 18 years or older registered with Alberta Health and Wellness from April 1, 1997 to March 31, 2008. (B) Cohort of participants who had at least one outpatient serum creatinine measurement from May 1, 2002 to March 31, 2008.
Figure 2.
Cumulative risk of ESRD (in percentage) with advancing age for men and women at the index age of 40 years.
Figure 3.
Competing risk of death-adjusted cumulative risk of ESRD (in percentage) with advancing age by eGFR category for men and women at the index ages of 40 and 70 years. eGFR was categorized as ≥90, 60–89, 45–59, and 30–44 ml/min per 1.73 m2.
Comment in
- Lifetime risk of ESRD: a meaningful concept?
Eggers P. Eggers P. J Am Soc Nephrol. 2012 Sep;23(9):1444-6. doi: 10.1681/ASN.2012070733. Epub 2012 Aug 9. J Am Soc Nephrol. 2012. PMID: 22878959 Free PMC article. No abstract available.
Similar articles
- Kidney stones and kidney function loss: a cohort study.
Alexander RT, Hemmelgarn BR, Wiebe N, Bello A, Morgan C, Samuel S, Klarenbach SW, Curhan GC, Tonelli M; Alberta Kidney Disease Network. Alexander RT, et al. BMJ. 2012 Aug 29;345:e5287. doi: 10.1136/bmj.e5287. BMJ. 2012. PMID: 22936784 Free PMC article. - Short-term change in kidney function and risk of end-stage renal disease.
Turin TC, Coresh J, Tonelli M, Stevens PE, de Jong PE, Farmer CK, Matsushita K, Hemmelgarn BR. Turin TC, et al. Nephrol Dial Transplant. 2012 Oct;27(10):3835-43. doi: 10.1093/ndt/gfs263. Epub 2012 Jul 3. Nephrol Dial Transplant. 2012. PMID: 22764191 - Estimated glomerular filtration rate variability and risk of end-stage renal disease among patients with Stage 3 chronic kidney disease.
Perkins RM, Kirchner HL, Hartle JE, Bucaloiu ID. Perkins RM, et al. Clin Nephrol. 2013 Oct;80(4):256-62. doi: 10.5414/CN107905. Clin Nephrol. 2013. PMID: 23993165 - Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial.
Ishani A, Grandits GA, Grimm RH, Svendsen KH, Collins AJ, Prineas RJ, Neaton JD. Ishani A, et al. J Am Soc Nephrol. 2006 May;17(5):1444-52. doi: 10.1681/ASN.2005091012. Epub 2006 Apr 12. J Am Soc Nephrol. 2006. PMID: 16611715 Clinical Trial. - Importance of glomerular filtration rate change as surrogate endpoint for the future incidence of end-stage renal disease in general Japanese population: community-based cohort study.
Kanda E, Usui T, Kashihara N, Iseki C, Iseki K, Nangaku M. Kanda E, et al. Clin Exp Nephrol. 2018 Apr;22(2):318-327. doi: 10.1007/s10157-017-1463-0. Epub 2017 Sep 7. Clin Exp Nephrol. 2018. PMID: 28884361 Free PMC article.
Cited by
- Patient participation in end-stage kidney disease care: variation over time and effects of staff-directed interventions - a quasi-experimental study.
Hurtig C, Bendtsen M, Årestedt L, Uhlin F, Eldh AC. Hurtig C, et al. BMC Nephrol. 2023 Sep 11;24(1):265. doi: 10.1186/s12882-023-03313-z. BMC Nephrol. 2023. PMID: 37691126 Free PMC article. - Plasma Biomarkers as Risk Factors for Incident CKD.
Sarnak MJ, Katz R, Ix JH, Kimmel PL, Bonventre JV, Schelling J, Cushman M, Vasan RS, Waikar SS, Greenberg JH, Parikh CR, Coca SG, Sabbisetti V, Jogalekar MP, Rebholz C, Zheng Z, Gutierrez OM, Shlipak MG. Sarnak MJ, et al. Kidney Int Rep. 2022 Mar 25;7(7):1493-1501. doi: 10.1016/j.ekir.2022.03.018. eCollection 2022 Jul. Kidney Int Rep. 2022. PMID: 35812266 Free PMC article. - Treating Early-Stage CKD With New Medication Therapies: Results of a CKD Patient Survey Informing the 2020 NKF-FDA Scientific Workshop on Clinical Trial Considerations for Developing Treatments for Early Stages of Common, Chronic Kidney Diseases.
Damron KC, Friedman R, Inker LA, Thompson A, Grams ME, Guðmundsdóttir H, Willis K, Manley T, Heerspink HL, Weiner DE. Damron KC, et al. Kidney Med. 2022 Mar 7;4(4):100442. doi: 10.1016/j.xkme.2022.100442. eCollection 2022 Apr. Kidney Med. 2022. PMID: 35372821 Free PMC article. - The validity of Dutch health claims data for identifying patients with chronic kidney disease: a hospital-based study in the Netherlands.
van Oosten MJM, Brohet RM, Logtenberg SJJ, Kramer A, Dikkeschei LD, Hemmelder MH, Bilo HJG, Jager KJ, Stel VS. van Oosten MJM, et al. Clin Kidney J. 2020 Nov 9;14(6):1586-1593. doi: 10.1093/ckj/sfaa167. eCollection 2021 Jun. Clin Kidney J. 2020. PMID: 34276977 Free PMC article. - Evidence-Based Decision Making 6: Administrative Databases as Secondary Data Source for Epidemiologic and Health Service Research.
Chowdhury TT, Hemmelgarn BR. Chowdhury TT, et al. Methods Mol Biol. 2021;2249:483-499. doi: 10.1007/978-1-0716-1138-8_26. Methods Mol Biol. 2021. PMID: 33871860
References
- US Renal Data System: USRDS 2007 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, 2007. Available at: http://www.usrds.org/adr.htm Accessed January 15, 2012.
- Zelmer JL: The economic burden of end-stage renal disease in Canada. Kidney Int 72: 1122–1129, 2007 - PubMed
- Turin TC, Kokubo Y, Murakami Y, Higashiyama A, Rumana N, Watanabe M, Okamura T: Lifetime risk of acute myocardial infarction in Japan. Circ Cardiovasc Qual Outcomes 3: 701–703, 2010 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous